558 related articles for article (PubMed ID: 19122263)
1. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider JP
Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
[TBL] [Abstract][Full Text] [Related]
3. [Alendronate for treatment of osteoporoses].
Harada A
Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
[TBL] [Abstract][Full Text] [Related]
4. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
Stepan JJ; Burr DB; Pavo I; Sipos A; Michalska D; Li J; Fahrleitner-Pammer A; Petto H; Westmore M; Michalsky D; Sato M; Dobnig H
Bone; 2007 Sep; 41(3):378-85. PubMed ID: 17597017
[TBL] [Abstract][Full Text] [Related]
5. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
6. Atypical fractures on long term bisphosphonates therapy.
Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
[TBL] [Abstract][Full Text] [Related]
7. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Angthong C; Angthong W
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
[TBL] [Abstract][Full Text] [Related]
8. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
[TBL] [Abstract][Full Text] [Related]
10. Is cortical bone hip? What determines cortical bone properties?
Epstein S
Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
[TBL] [Abstract][Full Text] [Related]
11. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
Hosoi T
Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
[TBL] [Abstract][Full Text] [Related]
12. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
13. [Reliably combined to combat osteoporosis].
MMW Fortschr Med; 2005 Dec; 147(51-52):63. PubMed ID: 16402714
[No Abstract] [Full Text] [Related]
14. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
15. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
[TBL] [Abstract][Full Text] [Related]
16. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
17. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
18. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
20. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
